Messenger RNA (mRNA) is the molecule that carries a recipe from a cell’s genetic blueprint to the cell’s protein-making machinery, telling it which proteins to build and when. Investors care because mRNA can be used as a flexible platform to develop drugs and vaccines quickly—like swapping recipes in a kitchen—which affects a company’s potential market size, manufacturing needs, regulatory review, and revenue prospects.
self-amplifying messenger rnamedical
Self-amplifying messenger RNA (sa-mRNA) is a laboratory-designed strand of RNA that, in addition to carrying instructions to make a target protein, also encodes a small set of viral replication enzymes so those instructions can be copied inside a cell. Like a message that brings its own photocopier, sa-mRNA can produce more protein from a smaller initial dose, which matters to investors because it can affect manufacturing scale, dosing, cost, and the commercial potential of RNA-based vaccines and therapies.
small interfering rnamedical
Small interfering RNA (siRNA) are short, lab-made strands of genetic material that act like a mute button inside cells, binding to a specific genetic message and preventing a particular protein from being made. For investors, siRNA represents a drug technology with the potential to treat diseases by precisely turning off harmful genes, which can mean high development costs, regulatory hurdles, intellectual property value, and the possibility of breakthrough therapies that change market dynamics.
ornithine transcarbamylasemedical
An enzyme in the liver cell machinery that helps convert toxic ammonia into urea for safe removal from the body, part of the urea cycle. Think of it as a specific worker on a factory line that processes a harmful raw material into a harmless product; when it is missing or defective, ammonia builds up and can cause serious illness. Its relevance to investors lies in its role as a target for diagnostic tests, drugs, and genetic therapies that can create markets or regulatory milestones in healthcare.
lipid-mediated deliverytechnical
Lipid-mediated delivery is a method for packaging drugs or genetic material inside tiny fat-based carriers so they can travel through the body and enter cells. Think of the lipids as biodegradable bubbles that protect the payload from breakdown in the bloodstream and help it fuse with cell membranes. It matters to investors because this delivery approach can influence a therapy’s effectiveness, safety profile, manufacturing complexity, regulatory review, and commercial scalability.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SAN DIEGO--(BUSINESS WIRE)--
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026.
Arcturus Therapeutics Second Quarter 2026 Earnings Conference Call
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. Please connect with us on X and LinkedIn.
